{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:02:16Z","timestamp":1756382536250,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>In the UK, over 900,000 patients have chronic heart failure and more than 60,000 develop the condition each year.1,2 Patients with heart failure suffer significantly reduced quality of life and have a poor prognosis. It is estimated that heart failure accounts for around 2% of the total NHS budget, 70% of which is related to the costs of hospitalisation.3 The main pharmacological interventions that are currently used to manage heart failure include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor antagonists (AIIRAs), beta-blockers and aldosterone antagonsists. \u03b8Ivabradine (Procoralan \u2013 Servier) is a \u201cpure heart rate lowering agent, acting by selective and specific inhibition of the cardiac pacemaker <jats:bold>\n                     <jats:italic>I<\/jats:italic>\n                  <\/jats:bold>\n                  <jats:sub>f<\/jats:sub> current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate\u201d.4 It has been licensed in the UK since 2006 for the symptomatic treatment of chronic stable angina in patients with normal sinus rhythm.5 Earlier this year ivabradine was granted marketing authorisation for the treatment of chronic heart failure. Here we review the role of ivabradine for this new indication. <\/jats:p>","DOI":"10.1136\/dtb.2012.10.0136","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T12:32:53Z","timestamp":1349958773000},"page":"117-120","source":"Crossref","is-referenced-by-count":3,"title":["Ivabradine for chronic heart failure?"],"prefix":"10.1136","volume":"50","member":"239","published-online":{"date-parts":[[2012,10,11]]},"reference":[{"key":"2025082723522602000_50.10.117.1","unstructured":"British Heart Foundation . Coronary heart disease statistics: heart failure supplement. 2002 edition. London: British Heart Foundation, 2002."},{"key":"2025082723522602000_50.10.117.2","first-page":"14","article-title":"Gender and heart failure: a population perspective","volume":"92 (suppl 3)","author":"Mehta","year":"2002","journal-title":"Heart"},{"key":"2025082723522602000_50.10.117.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(01)00198-2"},{"key":"2025082723522602000_50.10.117.4","unstructured":"Ivabradine. Summary of product characteristics, EU. Servier Laboratories Limited, February 2012."},{"key":"2025082723522602000_50.10.117.5","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2008.10.0026"},{"key":"2025082723522602000_50.10.117.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"2025082723522602000_50.10.117.7","unstructured":"National Institute for Health and Clinical ExcelIence, 2010. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care [online] Available: http:\/\/www.nice.org.uk\/guidance\/CG108 [Accessed 19 September 2012]."},{"key":"2025082723522602000_50.10.117.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.11.013"},{"key":"2025082723522602000_50.10.117.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812172"},{"key":"2025082723522602000_50.10.117.10","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.156034"},{"key":"2025082723522602000_50.10.117.11","unstructured":"NICOR: National Institute for Cardiovascular Outcomes Research, 2012. National heart failure audit 2010\u20132011 [online]. Available: http:\/\/www.ucl.ac.uk\/nicor\/audits\/heartfailure\/additionalfiles\/pdfs\/annualreports\/annual11.pdf [Accessed 19 September 2012]."},{"key":"2025082723522602000_50.10.117.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.6.585"},{"key":"2025082723522602000_50.10.117.13","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(87)90666-1"},{"key":"2025082723522602000_50.10.117.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.20.2313"},{"key":"2025082723522602000_50.10.117.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi190"},{"key":"2025082723522602000_50.10.117.16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)91029-6"},{"key":"2025082723522602000_50.10.117.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi555"},{"key":"2025082723522602000_50.10.117.18","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.1.42"},{"key":"2025082723522602000_50.10.117.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-11-200906020-00006"},{"key":"2025082723522602000_50.10.117.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"2025082723522602000_50.10.117.21","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M . Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study . Clin Res Cardiol [Epub ahead of print] 11 May 2012; DOI:10.1007\/s00392-012-0467-8.","DOI":"10.1007\/s00392-012-0467-8"},{"key":"2025082723522602000_50.10.117.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"2025082723522602000_50.10.117.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp358"},{"key":"2025082723522602000_50.10.117.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.06.098"},{"key":"2025082723522602000_50.10.117.25","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2011.01.0003"},{"key":"2025082723522602000_50.10.117.26","first-page":"1938","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"Int J Cardiol"},{"key":"2025082723522602000_50.10.117.27","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300041"},{"key":"2025082723522602000_50.10.117.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs004"},{"key":"2025082723522602000_50.10.117.29","unstructured":"National Institute for Health and Clinical ExcelIence, 2012. Heart failure (chronic)\u2014ivabradine: appraisal consultation document [online]. Available: http:\/\/guidance.nice.org.uk\/TA\/Wave26\/10\/Consultation\/DraftGuidance [Accessed 19 September 2012]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2012.10.0136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:52:37Z","timestamp":1756363957000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2012.10.0136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10,11]]},"published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1136\/dtb.2012.10.0136"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2012.10.0136","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}